Treatment of Onychomycosis: Pros and Cons of Antifungal Agents

Journal of Cutaneous Medicine and Surgery

Volumn 8, Issue 1, 2004, Pages 25-30

  Gupta, Aditya K ^a,b   Ryder, Jennifer E ^b   Skinner, Alayne R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CICLOPIROX; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; DIHYDROPYRIDINE; DOFETILIDE; FLUCONAZOLE; GLIPIZIDE; HYDROCHLOROTHIAZIDE; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PIMOZIDE; QUINIDINE; RIFAMPICIN; SIMVASTATIN; TACROLIMUS; TERBINAFINE; THEOPHYLLINE; TOLBUTAMIDE; TRIAZOLAM; UNINDEXED DRUG; ZIDOVUDINE;

CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DOWN SYNDROME; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG INDICATION; ELDERLY CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MEDICAL DECISION MAKING; MEDLINE; ONYCHOMYCOSIS; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; COMORBIDITY; DIABETES MELLITUS; DRUG INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; ONYCHOMYCOSIS; TREATMENT OUTCOME;

EID: 1642268655     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-003-0109-x     Document Type: Review

References (54)

1. Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000; 39:746-753.
2. Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998; 139:665-671.
3. Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000; 10:379-384.
4. Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000; 14:466-469.
5. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. Int J Dermatol 1997; 36:783-787.
6. Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997; 136:786-789.
7. Millikan LE. Role of oral antifungal agents for the treatment of superficial fungal infections in immunocompromised patients. Cutis 2001; 68:6-14.
8. Gupta AK, Scher RK, Doncker P De. Current management of onychomycosis. An overview. Dermatol Clin 1997; 15:121-135.
9. Gupta AK, Shear NH. The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venereol 1999; 13:1-13.
10. Gupta AK, Shear NH. Safety review of the oral antifungal agents used to treat superficial mycoses. Int J Dermatol 1999; 38(Suppl 2):40-52.
11. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf 2000; 22:33-52.
12. Jaffe R. Onychomycosis: recognition, diagnosis, and management. Arch Fam Med 1998; 7:587-592.
13. Gupta AK, Rosso JQ Del. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int J Dermatol 2000; 39:401-411.
14. Sporanox® (Itraconazole) capsules prescribing information. Janssen Pharmaceutica Products, L.P. 2001. http://www.sporanox.com/prescribing.jsp.
15. Lamisil® (terbinafine hydrochloride tablets) prescibing information. Novartis Pharmaceuticals Corporation. 2001. http://www.lamisil.com/pi.jsp?checked = y.
16. Diflucan® prescribing information. Pfizer. 1998. http://www.diflucan.com/pi.html.
17. Goeteyn V, Naeyaert JM, Lambert J, et al. Is systemic autoimmune disease a risk factor for terbinafine-induced erythema multiforme? Br J Dermatol 2000; 142:578-579.
18. Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a post marketing surveillance study in 25,884 patients. Arch Dermatol 1997; 133:1213-1219.
19. Lovell MO, Speeg KV, Havranek RD, et al. Histologic changes resembling acute rejection in a liver transplant patient treated with terbinafine. Hum Pathol 2003; 34:187-189.
20. Penlac™ nail lacquer (ciclopirox) topical solution, 8% prescribing information. Dermik Laboratories Inc. 2000. http://www.dermik.com/prod/penlac/pi.html.
21. Seebacher C, Nietsch K-H, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of cicloprox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis 2001; 68(Suppl 2):17-22.
22. Gupta AK. Onychomycosis in the elderly. Drugs Aging 2000; 16:397-407.
23. Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000; 43:S81-S95.
24. Gupta AK, Sibbald G, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997; 36:395-402.
25. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000; 43:244-248.
26. Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol 2001; 44:479-484.
27. Smith EB, Stein LF, Fivenson DP, et al. Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. Int J Dermatol 2000; 39:861-864.
28. Gupta AK, Skinner AR, Baran R. Onychomycosis in children: an overview. J Drugs Dermatol 2003; 2:31-34.
29. Huang P, Paller AS. Itraconazole pulse therapy for dermatophyte onychomycosis in children. Arch Pediatr Adolesc Med 2000; 154:614-618.
30. Gupta AK, Nolting S, Prost Y de, et al. The use of itraconazole to treat cutaneous fungal infections in children. Dermatology 1999; 199:1-5.
31. Bonifaz A, Ibarra G. Onychomycosis in children: treatment with bifonazole-urea. Pediatr Dermatol 2000; 17:310-314.
32. Goulden V, Goodfield MJD. Treatment of childhood dermatophyte infections with oral terbinafine. Pediatr Dermatol 1995; 12:53-54.
33. Velthuis PJ, Nijenhuis M. Treatment of onychomycosis with terbinafine in patients with Down's syndrome. Br J Dermatol 1995; 133:144-146.
34. Lee KH, Kim YS, Kim MS, et al. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transplant Proc 1996; 28:1488-1489.
35. Nahass GT, Sisto M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993; 186:59-61.
36. Aly R, Berger T. Common superficial fungal infections in patients with AIDS. Clin Infect Dis 1996; 22(Suppl 2):S128-S132.
37. Rongioletti F, Persi A, Tripodi S, et al. Proximal white subungual onychomycosis: a sign of immunodeficiency. J Am Acad Dermatol 1994; 30:129-130.
38. Conant MA. The AIDS epidemic. J Am Acad Dermatol 1994; 31:S47-S50.
39. Cribier B, Mena ML, Rey D, et al. Nail changes in patients infected with human immunodeficiency virus. A prospective controlled study. Arch Dermatol 1998; 134:1216-1220.
40. Elmets CA. Management of common superficial fungal infections in patients with AIDS. J Am Acad Dermatol 1994; 31:S60-S63.
41. Herranz P, Garcia J, Lucas R De, et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafme. Br J Dermatol 1997; 137:577-580.
42. Pena-Penabad C, Garcia-Silva J, Almagro M, et al. Superficial white onychomycosis in a 3-year-old human immunodeficiency virus-infected child. J Eur Acad Dermatol Venereol 2001; 15:51-53.
43. Rich P. Onychomycosis and tinea pedis in patients with diabetes. J Am Acad Dermatol 2000; 43:S130-S134.
44. Levy LA. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 1997; 87:546-550.
45. Anarella JJ, Toth C, DeBello JA. Preventing complications in the diabetic patient with toenail onychomycosis. J Am Podiatr Med Assoc 2001; 91:325-328.
46. Albreski DA, Gross EG. The safety of itraconazole in the diabetic population. J Am Podiatr Med Assoc 1999; 89:339-345.
47. Verspeelt J, Marynissen G, Gupta AK, et al. Safety of itraconazole in diabetic patients. Dermatology 1999; 198:382-384.
48. Farkas B, Paul C, Dobozy A, et al. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 2002; 146:254-260.
49. Lamisil® (terbinafine hydrochloride tablets) product information. Novartis Pharmaceuticals Physicians' Desk Reference, 57. Thomson PDR, Montvale, NJ 2003, pp 2282-2283.
50. Lamisil® Novartis Pharmaceuticals Compendium of Pharmaceuticals and Speicalties The Canadian Drug Reference for Health Professionals. Canadian Phamacists Association, Ottawa, ON 2003, pp 862-864.
51. Sporanox® (Itraconazole) capsules product information Janssen Pharmaceutica Products, L.P. Physicians' Desk Reference Thomson PDR, Montvale, NJ 2003, pp 1790-1794.
52. Sporanox® capsules. Janssen-Ortho Compendium of Pharmaceuticals and Specialties The Canadian Drug Reference for Health Professionals. Canadian Pharmacists Association, Ottawa, ON 2003, pp 1595-1598.
53. Diflucan® product information Pfizer. Physicians' Desk Reference, 57 Thomson PDR, Montvale, NJ 2003, pp 2594-2599.
54. Diflucan Pfizer Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Canadian Pharmacists Association, Ottawa, ON 2003, pp 504-507.